genomic determinants of response to tmt for patients with muscle-invasive bladder cancer
Published 1 year ago • 66 plays • Length 2:35Download video MP4
Download video MP3
Similar videos
-
2:05
improving responses to trimodality therapy in patients with muscle-invasive bladder cancer
-
4:42
bladder-sparing trimodality therapy for muscle-invasive bladder cancer
-
2:56
computational genomic approaches to treatment of genitourinary cancers
-
1:43
survivorship issues for patients with bladder cancer
-
2:00
permed2018_gepard - genomic determinants of therapy response in etv6-runx1 leukemia
-
11:09
genomic testing: unlocking the potential of precision oncology for patients and for health systems
-
7:07
measuring response in non-muscle invasive bladder cancer
-
1:43
us mortality trends for bladder cancer
-
3:47
cell-free utdna may predict transurethral resection of bladder tumour pathology in nmibc
-
33:15
the use of emerging genomic technologies to predict tumor response and drug resistance
-
5:00
decision support for precision oncology: evolving from monotherapy to genomically informed combi...
-
7:15
optimizing biomarker testing for patients with metastatic prostate cancer
-
49:27
muscle invasive bladder cancer w/ dr. siamak daneshmand | backtable urology podcast ep. 25
-
23:50
bladder sparing regimens for muscle invasive disease: should we be doing this more?
-
59:47
clinical proteogenomic tumor analysis consortium
-
1:03:01
webinar: the advancing utility of genomic testing in routine oncology practice
-
1:04:06
modeling mechanisms of therapeutic response and resistance
-
15:11
novel targeted medicine to modulate tumor‐associated macrophages for the treatment of breast cancer
-
4:33
tailorx: genomic test helps identify low-risk women who do not need chemotherapy